Australia's Control Bionics jumps after FDA listing for NeuroStrip device
BUZZ-Australia's Control Bionics jumps after FDA listing for NeuroStrip device ** Shares of Australia's Control Bionics CBL.AX rise as much as 10.8% to A$0.072, posting their biggest intraday pct gain since June 5
** Stock hits its highest level since July 16
** Neurotechnology firm says its NeuroStrip surface EMG wearable platform has been registered and listed with the U.S. Food and Drug Administration (FDA) as a medical device
** NeuroStrip offers insight into muscle activation and intent through bioelectric signals and spatial movements
** CBL has also submitted applications for regulatory approval in additional key jurisdictions, including registration with the Therapeutic Goods Administration (TGA) in Australia, among others
** Stock up nearly 15% this year, including the day's move
(Reporting by Rajasik Mukherjee in Bengaluru)
Recent news on Control Bionics
See all newsBrief: Control Bionics Posts Full-Year Loss Attributable Of A$7.3 Million
Brief: Control Bionics Sees FY27 Revenue Growth Of 50% Over FY26
Brief: Control Bionics Says Medicare Billing Code Secured For Nextlevel Speech Devices
Brief: Control Bionics Receives UK MHRA Registration For Neurostrip
Australia's Control Bionics jumps after FDA listing for NeuroStrip device